ESTRO 2023 - Abstract Book

S1031

Digital Posters

ESTRO 2023

NACT No

50

24.4 75.6

yes

155

Surgery BCS

34

16.6

MRM

171

83.4

Radiotherapy Site Breast Only

13

6.3

Breast + SCF

21

10.2

chest wall (CW)

4

2.0

CW + SCF

151

73.7

CW+SCF+Axilla

16

7.8

Radiotherapy dose 26Gy/5#s

171

83.4

26Gy/5#s + 12.5Gy/5#s

32

15.6

26Gy/5#s & 31Gy/5#s

2

1.0

Acute Skin Toxicity (RTOG) 0

33

16.1

1

162

79.0

2

5

2.4 2.4

3

5

Acute Odynphagia (RTOG) 0

53

25.9

1

144

70.2

2

6

2.9

3

2

1.0

Treatment Failure No

180

87.8

Yes

25

12.2

Conclusion Extreme hypo-fractionation is safe and feasible option even with locally advanced breast cancer but long term follow up and well-designed randomized trials are warranted to establish it in the locally advanced breast cancer.

PO-1288 Preliminary toxicity data on Trastuzumab emtansine and concomitant radiotherapy in adjuvant setting

C.M.E. Perotti 1 , D. Sartori 2 , C. De Rossi 3 , L. Lamin 1 , I. Abu Rumeileh 1

1 Ospedale dell'Angelo, Radiotherapy Department, Venezia - Mestre, Italy; 2 Ospedale di Mirano e Dolo, Department of Medical Oncology , Mirano (VE), Italy; 3 Ospedale dell'Angelo, Department of Medical Oncology, Venezia - Mestre, Italy

Purpose or Objective